TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31959650

Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31959735

Group type: EXPERIMENTAL
Intervention: Cisplatin-resistant target genes and genes associated with poor prognosis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: ssGSEA analysis
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: TMB analysis
Number of subjects: 156
Study: 31959992

Group type: EXPERIMENTAL
Intervention: Hu19-CD828Z T cells
Number of subjects: 20

Group type: COMPARATOR
Intervention: FMC63-28Z T cells
Number of subjects: 20
Study: 31960250

Group type: EXPERIMENTAL
Intervention: Multiple Sclerosis (MS) patients
Number of subjects: 1663

Group type: EXPERIMENTAL
Intervention: Neuromyelitis Optica Spectrum Disorder (NMOSD) patients
Number of subjects: 1663
Study: 31960589

Group type: EXPERIMENTAL
Intervention: Online group (online counselling and online, supervised, HIV self-testing)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Mixed group (online pre-test counselling and offline HIV testing)
Number of subjects: 564

Group type: EXPERIMENTAL
Intervention: Offline group (offline HIV counselling and testing)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Online group
Number of subjects: 564

Group type: COMPARATOR
Intervention: <17 years old at first sex
Number of subjects: 564

Group type: COMPARATOR
Intervention: Amphetamine-type stimulants use in the past six months
Number of subjects: 564

Group type: COMPARATOR
Intervention: No/single sex partner in the past six months
Number of subjects: 564
Study: 31960816

Group type: EXPERIMENTAL
Intervention: Endothelial progenitor cells (EPCs) counted with flow cytometry, assessed at baseline, days 7, 30, and 90.
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Changes in circulating EPC numbers and/or functional capacity.
Number of subjects: 100
Study: 31960953

Group type: EXPERIMENTAL
Intervention: Peroperative carcinoembryonic antigen (CEA)-specific fluorescence imaging during cytoreductive surgery-hyperthermic intraperitoneal chemotherapy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: SGM-101
Number of subjects: 14
Study: 31961057

Group type: EXPERIMENTAL
Intervention: Nano+™ stent implantation
Number of subjects: 2481
Study: 31961331

Group type: EXPERIMENTAL
Intervention: eHealth self-management intervention (EPIO) including one face-to-face introduction session and 9 app-based educational and exercise-based modules
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Stakeholder input and user-centered design approach
Number of subjects: 53
Study: 31961766

Group type: EXPERIMENTAL
Intervention: Lenvatinib plus pembrolizumab (200 mg intravenously every 3 weeks)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Lenvatinib 20 mg/d plus pembrolizumab (recommended phase II dose)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Lenvatinib 24 mg/d plus pembrolizumab (initial dose level)
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Subsequent dose-de-escalation cohort (lenvatinib 20 mg/d plus pembrolizumab)
Number of subjects: 137
Study: 31961822

Group type: EXPERIMENTAL
Intervention: G6PD-deficient RBCs
Number of subjects: 37

Group type: COMPARATOR
Intervention: G6PD-normal RBCs
Number of subjects: 37
Study: 31961826

Group type: EXPERIMENTAL
Intervention: 100 mg mirabegron for 4 weeks
Number of subjects: 14
Study: 31961829

Group type: EXPERIMENTAL
Intervention: Mirabegron treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conditioned media from adipocytes treated with mirabegron
Number of subjects: 0
Study: 31963294

Group type: EXPERIMENTAL
Intervention: RNA sequencing of 12 ccRCC patients with aggressive characteristics
Number of subjects: 24

Group type: COMPARATOR
Intervention: RNA sequencing of 12 matched ccRCC patients without aggressive characteristics
Number of subjects: 24
Study: 31964290

Group type: EXPERIMENTAL
Intervention: Early initiation of DOACs (≤3 days after stroke onset)
Number of subjects: 1192

Group type: COMPARATOR
Intervention: Late initiation of DOACs (≥4 days after stroke onset)
Number of subjects: 1192
Study: 31964386

Group type: EXPERIMENTAL
Intervention: Boys
Number of subjects: 671

Group type: EXPERIMENTAL
Intervention: Girls
Number of subjects: 671

Group type: COMPARATOR
Intervention: Boys and Girls
Number of subjects: 671
Study: 31964391

Group type: EXPERIMENTAL
Intervention: Care Coordination Instrument (CCI)
Number of subjects: 140
Study: 31964568

Group type: EXPERIMENTAL
Intervention: Spiral-Z iliac leg graft
Number of subjects: 599
Study: 31964784

Group type: EXPERIMENTAL
Intervention: CUE-101, a novel therapeutic fusion protein composed of a human leukocyte antigen (HLA) complex, an HPV16 E7 peptide epitope, reduced affinity human IL2 molecules, and an effector attenuated human IgG1 Fc domain.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CUE-101
Number of subjects: 0
Study: 31965161

Group type: EXPERIMENTAL
Intervention: High Hemoglobin Glycation Index (HGI) subgroup
Number of subjects: 6829

Group type: EXPERIMENTAL
Intervention: Low to high HGI subgroups
Number of subjects: 6829

Group type: EXPERIMENTAL
Intervention: High HGI
Number of subjects: 6829

Group type: COMPARATOR
Intervention: HbA1c
Number of subjects: 6829

Group type: COMPARATOR
Intervention: FPG and 2hPG
Number of subjects: 6829
Study: 31965820

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 31967219

Group type: EXPERIMENTAL
Intervention: Nintendo WiiTM gaming system
Number of subjects: 60
Study: 31967304

Group type: EXPERIMENTAL
Intervention: Recombinant hCG 250 μg
Number of subjects: 160
Study: 31967355

Group type: EXPERIMENTAL
Intervention: Phosphodiesterase 10A PET imaging
Number of subjects: 45

Group type: COMPARATOR
Intervention: Healthy controls (N=45)
Number of subjects: 45
Study: 31969132

Group type: EXPERIMENTAL
Intervention: Vigorous harness-supported treadmill training in a room cooled to 16 °C (10 weeks; 3 times/week)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Vigorous harness-supported treadmill training
Number of subjects: 10
Study: 31969330

Group type: EXPERIMENTAL
Intervention: ABBV-838 (3+3 design) intravenously starting from 0.6 mg/kg up to 6.0 mg/kg for 3-week dosing intervals (Q3W), continued for up to 24 months.
Number of subjects: 75
Study: 31969335

Group type: EXPERIMENTAL
Intervention: Ipilimumab plus nivolumab
Number of subjects: 32
Study: 31969338

Group type: EXPERIMENTAL
Intervention: Decitabine and Vorinostat with chemotherapy (vincristine, dexamethasone, mitoxantrone, PEG-asparaginase)
Number of subjects: 23
Study: 31969366

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate diabetes prevention programme (LC-DPP)
Number of subjects: 21
Study: 31970051

Group type: EXPERIMENTAL
Intervention: 1-level CDA
Number of subjects: 942

Group type: COMPARATOR
Intervention: 2-level CDA
Number of subjects: 942

Group type: EXPERIMENTAL
Intervention: 1-level ACDF
Number of subjects: 942

Group type: COMPARATOR
Intervention: 2-level ACDF
Number of subjects: 942
Study: 31970446

Group type: EXPERIMENTAL
Intervention: Lower MRC sum score at ICU discharge
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Abnormal CMAP
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: MRC in MRC&CMAP-cohort
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: Low MRC in survivors
Number of subjects: 883

Group type: EXPERIMENTAL
Intervention: MRC ≤ 55
Number of subjects: 883
Study: 31970594

Group type: EXPERIMENTAL
Intervention: WBRT with SIB (25 or 37.5 Gy WBRT + 45 or 52.5 Gy SIB to gross lesions in 10 or 15 fractions)
Number of subjects: 13
Study: 31970894

Group type: EXPERIMENTAL
Intervention: Skin Mark clipped Axillary nodes Removal Technique (SMART)
Number of subjects: 14
Study: 31971541

Group type: EXPERIMENTAL
Intervention: Talimogene laherparepvec (T-VEC) plus pembrolizumab (200-mg flat dose) intravenously; T-VEC first dose ≤4 mL × 106 PFU/mL, subsequent doses ≤4 mL × 108 PFU/mL, injected into palpable tumor site(s) on day 1 of each 21-day cycle.
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: T-VEC plus pembrolizumab
Number of subjects: 20
Study: 31971567

Group type: EXPERIMENTAL
Intervention: IV posaconazole 300 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IV posaconazole 400 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IV posaconazole
Number of subjects: 24
Study: 31971890

Group type: EXPERIMENTAL
Intervention: Lymphedema Functioning, Disability, and Health Questionnaire
Number of subjects: 0
Study: 31972008

Group type: EXPERIMENTAL
Intervention: rs9349379-G allele
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Zibotentan (ETA antagonist)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Contemporary reference genome bank control subjects
Number of subjects: 185
Study: 31972009

Group type: EXPERIMENTAL
Intervention: ST2 (>26 ng/mL) in children age 10 years or younger
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: TNFR1 (>3441 pg/mL) in children age 10 years or younger
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: REG3α (>25 ng/mL) in children age 10 years or younger
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ST2 (>26 ng/mL) in patients older than age 10 years
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: TNFR1 (>3441 pg/mL) in patients older than age 10 years
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: REG3α (>25 ng/mL) in patients older than age 10 years
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ST2 before HCT in children age 10 years or younger
Number of subjects: 415

Group type: EXPERIMENTAL
Intervention: ST2, TNFR1, and REG3α in the first 3 weeks after HCT
Number of subjects: 415
Study: 31972476

Group type: EXPERIMENTAL
Intervention: Norditropin® (somatropin; Novo Nordisk A/S, Denmark) administered at the discretion of the treating physician.
Number of subjects: 3180

Group type: EXPERIMENTAL
Intervention: NordiNet® IOS (n=971) and ANSWER (n=304) studies data.
Number of subjects: 3180
Study: 31972852

Group type: EXPERIMENTAL
Intervention: Smartphone mHealth application
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Wearable tracking device (Apple watch)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both mHealth technologies
Number of subjects: 10
Study: 31973598

Group type: EXPERIMENTAL
Intervention: Live video-supervised exercise (3 times/week) and nutrition sessions (1 time/week) during the 12-16 week intervention phase
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Live video-supervised exercise and nutrition sessions during the 12-16 week maintenance phase (1 time/week) and self-directed exercise sessions (2 times/week)
Number of subjects: 14
Study: 31973779

Group type: EXPERIMENTAL
Intervention: Whole-blood PUFA assessment
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Total PUFA
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: n-6 PUFA
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: n-3 long-chain PUFA (LCPUFA)
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: MA:AA ratio
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Linoleic acid
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Monocyte counts
Number of subjects: 174
Study: 31973980

Group type: EXPERIMENTAL
Intervention: Cavum septum pellucidum (CSP) volume
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Hippocampal volume
Number of subjects: 171
Study: 31974103

Group type: EXPERIMENTAL
Intervention: Bariatric surgery
Number of subjects: 0
Study: 31974140

Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin T (hsTNT)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: N-terminal pro-brain natriuretic peptide serum levels
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 3 Tesla (3T) magnetic resonance neurography (MRN)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (subjects without diabetes)
Number of subjects: 51
Study: 31974144

Group type: EXPERIMENTAL
Intervention: Glucagon at high physiological levels
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glucagon at basal levels
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (healthy lean participants)
Number of subjects: 30
Study: 31974203

Group type: EXPERIMENTAL
Intervention: AG-348 (Mitapivat)
Number of subjects: 15
Study: 31974565

Group type: EXPERIMENTAL
Intervention: Absence of HLA-DRB5
Number of subjects: 10413

Group type: EXPERIMENTAL
Intervention: HLA-DQB*06:02
Number of subjects: 10413

Group type: EXPERIMENTAL
Intervention: HLA-DQA*01:02
Number of subjects: 10413

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*15:01~DQA1*01:02~DQB1*06:02 haplotype
Number of subjects: 10413

Group type: EXPERIMENTAL
Intervention: HLA-DRB1*07:01~DQA1*02:01~DQB1*03:03 haplotype
Number of subjects: 10413
Study: 31974680

Group type: EXPERIMENTAL
Intervention: Dynamic modeling for primary tumors (PT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dynamic modeling for metastatic lymph nodes (MLN)
Number of subjects: 0
Study: 31975350

Group type: EXPERIMENTAL
Intervention: Acidified human milk fortifier (HMF)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Non-acidified human milk fortifier (HMF)
Number of subjects: 152
Study: 31975503

Group type: EXPERIMENTAL
Intervention: 4-week lower limb exercise programme
Number of subjects: 54
Study: 31975539

Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (Brief-IPQ)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Qualitative analysis of patient interviews
Number of subjects: 213
Study: 31975781

Group type: EXPERIMENTAL
Intervention: Watermelon-enhanced IMAGINE intervention (n=15)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Basic health education via email and blogs (Control group, n=8)
Number of subjects: 23
Study: 31976385

Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) with other interventions in Ethiopia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Interpersonal communication (IPC) alone or with mass media in Vietnam
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Near-monthly IPC visits in Bangladesh and Ethiopia
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: One IPC visit in Vietnam
Number of subjects: 3
Study: 31977002

Group type: EXPERIMENTAL
Intervention: Avadomide (3 to 5 mg) administered on continuous or intermittent schedules until unacceptable toxicity, disease progression, or withdrawal.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Avadomide (3 to 5 mg) administered on intermittent 5/7-day schedule.
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Avadomide in classifier-positive DLBCL patients (de novo).
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Avadomide in classifier-negative DLBCL patients (de novo).
Number of subjects: 97
Study: 31977005

Group type: EXPERIMENTAL
Intervention: Avadomide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Classifier-negative patients
Number of subjects: 0
Study: 31977016

Group type: EXPERIMENTAL
Intervention: Pre-frailty
Number of subjects: 2369

Group type: EXPERIMENTAL
Intervention: Frailty
Number of subjects: 2369
Study: 31977454

Group type: EXPERIMENTAL
Intervention: Modified Reflux Symptom Questionnaire-electronic Diary (mRESQ-eD)
Number of subjects: 30
Study: 31978210

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg administered by IV infusion once weekly for weeks 1 to 8, every 2 weeks for weeks 9 to 24, and every 4 weeks thereafter until progression or unacceptable toxicity, for up to 24 months.
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Daratumumab 16 mg/kg administered by IV infusion.
Number of subjects: 22
Study: 31978221

Group type: EXPERIMENTAL
Intervention: Crovalimab (680 mg; 4 mL), administered subcutaneously once every 4 weeks
Number of subjects: 29
Study: 31978886

Group type: EXPERIMENTAL
Intervention: ROTEM-based therapy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Non-ROTEM group
Number of subjects: 37
Study: 31980020

Group type: EXPERIMENTAL
Intervention: 1-1-8 wash-in scheme for sevoflurane LFA
Number of subjects: 199

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 199
Study: 31980121

Group type: EXPERIMENTAL
Intervention: Diabetes technology use
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guidelines and educational material for clinicians and caregivers
Number of subjects: 0
Study: 31980408

Group type: EXPERIMENTAL
Intervention: Metastasis-free survival (MFS)
Number of subjects: 1207

Group type: EXPERIMENTAL
Intervention: Metastasis development
Number of subjects: 1207
Study: 31980466

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks for 2 years or until progression, intolerable toxicity, or physician/patient decision
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 107
Study: 31980497

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Moxifloxacin
Number of subjects: 0
Study: 31980830

Group type: EXPERIMENTAL
Intervention: Finetech Brindley Bladder System (FBBS) implantation without posterior rhizotomy
Number of subjects: 1
Study: 31980868

Group type: EXPERIMENTAL
Intervention: cART-treated PLHIVs with microalbuminuria
Number of subjects: 30

Group type: COMPARATOR
Intervention: cART-treated PLHIVs without microalbuminuria (controls)
Number of subjects: 30
Study: 31981321

Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β in HFpEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β in HFrEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β after LVAD in HFrEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Circulating NRG1-β after HTx in HFrEF
Number of subjects: 193

Group type: COMPARATOR
Intervention: Circulating NRG1-β in healthy controls
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Higher NRG1-β in HFrEF
Number of subjects: 193

Group type: EXPERIMENTAL
Intervention: Association of NRG1-β with outcomes in HFpEF
Number of subjects: 193
Study: 31981731

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 31981986

Group type: EXPERIMENTAL
Intervention: PTB/LBW babies
Number of subjects: 430

Group type: COMPARATOR
Intervention: FTB/NBW babies
Number of subjects: 430
Study: 31982162

Group type: EXPERIMENTAL
Intervention: Early BM-MNC treatment (5-7 days after AMI)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Late BM-MNC treatment (3-4 weeks after AMI)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 149
Study: 31982391

Group type: EXPERIMENTAL
Intervention: Lower fluid volumes
Number of subjects: 637

Group type: COMPARATOR
Intervention: Higher fluid volumes
Number of subjects: 637
Study: 31982461

Group type: EXPERIMENTAL
Intervention: Hunger (pre-lunch)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Satiety (post-lunch)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Mood assessment
Number of subjects: 15
Study: 31982610

Group type: EXPERIMENTAL
Intervention: Endoscopic eradication therapy (EET) leading to complete eradication of intestinal metaplasia (CE-IM)
Number of subjects: 807
Study: 31983307

Group type: EXPERIMENTAL
Intervention: Born preterm
Number of subjects: 206

Group type: COMPARATOR
Intervention: Born full-term
Number of subjects: 206
Study: 31983322

Group type: EXPERIMENTAL
Intervention: Ultrasound-accelerated thrombolysis and percutaneous transluminal venoplasty
Number of subjects: 78
Study: 31983321

Group type: EXPERIMENTAL
Intervention: Polygenic risk score (PRS) based on CAD risk variants
Number of subjects: 1645
Study: 31983496

Group type: EXPERIMENTAL
Intervention: Early rule-out pathway for myocardial infarction (postimplementation)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Standard care with hospital admission (preimplementation)
Number of subjects: 49
Study: 31983637

Group type: EXPERIMENTAL
Intervention: Scene-oriented images
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Object-oriented images
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Drawing tasks with minimal memory load
Number of subjects: 2000
Study: 31983669

Group type: EXPERIMENTAL
Intervention: High deep dyspareunia and BPFT
Number of subjects: 163

Group type: COMPARATOR
Intervention: No or low deep dyspareunia
Number of subjects: 163

Group type: COMPARATOR
Intervention: High deep dyspareunia but no BPFT
Number of subjects: 163
Study: 31984235

Group type: EXPERIMENTAL
Intervention: LDL-c less than 70 mg/dL
Number of subjects: 3760

Group type: COMPARATOR
Intervention: LDL-c of 100 ± 10 mg/dL
Number of subjects: 3760
Study: 31984244

Group type: EXPERIMENTAL
Intervention: Fractional doses of Yellow Fever vaccines
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard doses of Yellow Fever vaccines
Number of subjects: 0
Study: 31984451

Group type: EXPERIMENTAL
Intervention: Nevanimibe HCl at doses ranging from 1.6 mg/kg/day to 158.5 mg/kg/day
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Nevanimibe HCl
Number of subjects: 63
Study: 31984470

Group type: EXPERIMENTAL
Intervention: Infantile Tremor Syndrome (ITS)
Number of subjects: 92

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 92
Study: 31985097

Group type: EXPERIMENTAL
Intervention: Change in self-efficacy at 6 months
Number of subjects: 201
Study: 31985467

Group type: EXPERIMENTAL
Intervention: Donepezil 10 mg/day
Number of subjects: 241
Study: 31985803

Group type: EXPERIMENTAL
Intervention: High LVEF in women
Number of subjects: 4632

Group type: COMPARATOR
Intervention: Normal LVEF in women
Number of subjects: 4632

Group type: EXPERIMENTAL
Intervention: High LVEF in men
Number of subjects: 4632

Group type: COMPARATOR
Intervention: Normal LVEF in men
Number of subjects: 4632
Study: 31985868

Group type: EXPERIMENTAL
Intervention: Prognostic score based on age >68 years, abnormal vital signs, impaired mobility, and decision to admit.
Number of subjects: 2949

Group type: EXPERIMENTAL
Intervention: Prognostic score indicating two or more predictors present.
Number of subjects: 2949
Study: 31986140

Group type: EXPERIMENTAL
Intervention: Nifurtimox eflornithine combination therapy (NECT)
Number of subjects: 629
Study: 31986169

Group type: EXPERIMENTAL
Intervention: Periodontal scaling and root planing (SRP) treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (10 patients without periodontitis)
Number of subjects: 15
Study: 31986368

Group type: EXPERIMENTAL
Intervention: Enteral nutrition (EN) feeding protocol
Number of subjects: 439

Group type: COMPARATOR
Intervention: Control group (pre-implementation stage)
Number of subjects: 439
Study: 31987549

Group type: EXPERIMENTAL
Intervention: Head movement (motor task)
Number of subjects: 90
Study: 31987725

Group type: EXPERIMENTAL
Intervention: Meeting physical activity guideline (≥60 min/d of moderate-to-vigorous PA)
Number of subjects: 342

Group type: EXPERIMENTAL
Intervention: Meeting multiple guidelines (PA, sleep, and dietary)
Number of subjects: 342
Study: 31987880

Group type: EXPERIMENTAL
Intervention: Moderate-risk/short-distance group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moderate-risk/long-distance group
Number of subjects: 0